ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2645

Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries

Peter Izmirly1, Elizabeth Ferucci2, Aimee Hersh3, Mary Beth Son4, Cristina Drenkard5, S. Sam Lim6, Cynthia Crowson7, Ali Duarte-Garcia8, Jill Buyon9, Heather Gold9, Maria Dall'Era10, Patti Katz11, Laura Plantinga12, Jinoos Yazdany13, Jennifer Reihm14, Emily Somers15 and Hilary Parton16, 1New York University Grossman School of Medicine, New York, NY, 2Alaska Native Tribal Health Consortium, Anchorage, AK, 3University of Utah, Salt Lake City, UT, 4Boston Children's Hospital, Boston, MA, 5Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, 6Emory University School of Medicine, Atlanta, GA, 7Mayo Clinic, Stewartvillle, MN, 8Mayo Clinic, Rochester, MN, 9NYU Grossman School of Medicine, New York, NY, 10Division of Rheumatology, University of California, San Francisco, CA, 11UCSF, San Rafael, CA, 12University of California, San Francisco, San Francisco, CA, 13UCSF, San Francisco, CA, 14University of California, San Francisco, San Francisco, 15University of Michigan, Ann Arbor, MI, 16New York City Department of Health and Mental Hygiene, New York

Meeting: ACR Convergence 2025

Keywords: Epidemiology, meta-analysis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

Session Type: Abstract Session

Session Time: 9:30AM-9:45AM

Background/Purpose: Current estimates for age of SLE onset are limited, particularly for males and racial/ethnic groups in the United States. Leveraging five Centers for Disease Control and Prevention population-based SLE surveillance registries, which were developed to provide epidemiologic data for SLE across diverse regions of the US, we performed meta-analyses to estimate the age-specific incidence of SLE, overall and by sex and race/ethnicity.

Methods: The registries in Georgia, California, New York and the Indian Health Service (IHS) used the 1997 revised ACR classification criteria while the registry in Minnesota used the EULAR/ACR classification criteria for SLE as their primary case definitions. The surveillance periods ranged from 2002 to 2018. Age-specific incidence of SLE stratified by sex and race/ethnicity was obtained from each registry. Given the small number of registries and near-complete case ascertainment from each site, we performed a fixed-effects meta-analysis to estimate the pooled incidence using inverse-variance weighting, stratified by sex and race/ethnicity (females only due to small sample sizes for males), across the four state sites. Given the IHS registry focused solely on the American Indian/Alaska Native (AI/AN) population, their data was included separately in the female racial/ethnic estimates and not as part of the pooled estimates. To examine age-specific patterns of diagnoses, we then estimated the percentage of all SLE patients diagnosed among each age group, 0-19, 20-29, 30-39, 40-49, 50-59, 60-69, ≥70 years, from all the registries, weighted by the number of person-years contributed by the five sites.

Results: The registries contributed 939 incident classified cases of SLE from a mix of urban and rural areas. The fixed-effects model yielded overall incidence rates of 9.6 (95%CI: 8.9-10.3) and 1.7 (95%CI: 1.4-2.0) per 100,000 person-years among females and males, respectively, Figure 1. Incidence rates among females were highest for those aged 30-39 (13.8, 95%CI: 12.0-16.0), while rates among males were highest for those aged 60-69 (3.1, 95%CI: 1.9-5.0). Black females aged 20-39 and 40-59 had the highest SLE incidence rates (24.2, 95%CI: 20.5-28.6) and (24.3, 95%CI: 20.3-29.3), Figure 2. Among females diagnosed with SLE before age 20, incidence was highest among Asian (7.2, 95%CI: 3.8-13.5) and Black (6.4, 95%CI: 4.5-9.1) individuals. Among females diagnosed with SLE after age 60, incidence was highest among Black (13.8, 95%CI: 9.5-20.0) and AI/AN (9.4, 95%CI: 3.4-15.4) individuals. Weighted percentages (Table 1) show that 7.8% of those with SLE were diagnosed before age 20, while 17.9% were diagnosed after age 60. The largest proportion of individuals with SLE, 22.2%, were diagnosed between 30 and 39 years.

Conclusion: In this coordinated network of population-based SLE registries, age-specific incidence rates were obtained, and data were provided on males and previously understudied age groups. While female incidence rates were highest during the reproductive years, the incidence rates for males increased with age with the highest rates at ages 60-69. Overall, 18% of patients with SLE were diagnosed after age 60 and nearly 8% before age 20.

Supporting image 1Figure 1. SLE meta analysis incidence rates among females and males by age group.

Supporting image 2Figure 2. SLE meta-analysis incidence rates by race and ethnicity and age group among females.

Supporting image 3Age-Specific Patterns of Diagnoses


Disclosures: P. Izmirly: Hansoh Bio, 2; E. Ferucci: None; A. Hersh: None; M. Son: None; C. Drenkard: None; S. Lim: Accordant, 2, AstraZeneca, 2, Biogen, 5, BMS, 5, Genentech, 2, Gilead, 5, GSK, 2, Novartis, 5, UCB, 5; C. Crowson: None; A. Duarte-Garcia: None; J. Buyon: Artiva Biotherapeutics, 2, Biogen, 2, Bristol-Myers Squibb(BMS), 2, Celgene, 2, CLIMB Bio Operating, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Related Sciences, 2, UCB, 2; H. Gold: None; M. Dall'Era: AstraZeneca, 2, Aurinia, 2, Biogen, 2, Genentech, Inc., 2, GlaxoSmithKline (GSK), 2, Janssen, 2; P. Katz: None; L. Plantinga: None; J. Yazdany: AstraZeneca, 2, 5, Aurinia, 5, BMS Foundation, 5, 12, BMS Foundation, Gilead, 5, Pfizer, 2, UCB, 2; J. Reihm: None; E. Somers: None; H. Parton: None.

To cite this abstract in AMA style:

Izmirly P, Ferucci E, Hersh A, Son M, Drenkard C, Lim S, Crowson C, Duarte-Garcia A, Buyon J, Gold H, Dall'Era M, Katz P, Plantinga L, Yazdany J, Reihm J, Somers E, Parton H. Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/age-specific-incidence-of-systemic-lupus-erythematosus-in-the-united-states-a-meta-analysis-of-data-from-the-centers-for-disease-control-and-prevention-lupus-registries/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/age-specific-incidence-of-systemic-lupus-erythematosus-in-the-united-states-a-meta-analysis-of-data-from-the-centers-for-disease-control-and-prevention-lupus-registries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology